- Home
- IPA vs INAB Comparison
IPA vs INAB Comparison
Compare IPA & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPA
- INAB
- Stock Information
- Founded
- IPA 1983
- INAB 2016
- Country
- IPA United States
- INAB United States
- Employees
- IPA N/A
- INAB N/A
- Industry
- IPA Biotechnology: Pharmaceutical Preparations
- INAB Biotechnology: Pharmaceutical Preparations
- Sector
- IPA Health Care
- INAB Health Care
- Exchange
- IPA Nasdaq
- INAB Nasdaq
- Market Cap
- IPA 19.3M
- INAB 18.8M
- IPO Year
- IPA 2017
- INAB 2021
- Fundamental
- Price
- IPA $0.44
- INAB $0.16
- Analyst Decision
- IPA Strong Buy
- INAB Strong Buy
- Analyst Count
- IPA 2
- INAB 2
- Target Price
- IPA $4.00
- INAB $3.60
- AVG Volume (30 Days)
- IPA 471.7K
- INAB 821.9K
- Earning Date
- IPA 03-28-2025
- INAB 05-08-2025
- Dividend Yield
- IPA N/A
- INAB N/A
- EPS Growth
- IPA N/A
- INAB N/A
- EPS
- IPA N/A
- INAB N/A
- Revenue
- IPA $16,581,105.00
- INAB N/A
- Revenue This Year
- IPA $4.67
- INAB N/A
- Revenue Next Year
- IPA $14.15
- INAB N/A
- P/E Ratio
- IPA N/A
- INAB N/A
- Revenue Growth
- IPA 1.34
- INAB N/A
- 52 Week Low
- IPA $0.27
- INAB $0.13
- 52 Week High
- IPA $1.39
- INAB $1.74
- Technical
- Relative Strength Index (RSI)
- IPA 54.99
- INAB 35.83
- Support Level
- IPA $0.36
- INAB $0.15
- Resistance Level
- IPA $0.48
- INAB $0.18
- Average True Range (ATR)
- IPA 0.05
- INAB 0.02
- MACD
- IPA 0.01
- INAB 0.00
- Stochastic Oscillator
- IPA 74.85
- INAB 43.08
About IPA ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series proprietary and patented technologies. The company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.